MedTrace Logo

Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

NCT02340780 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-08-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out what effects a new drug, buparlisib, has on chronic lymphocytic leukemia.

Conditions

Interventions

DRUG

Buparlisib

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Sarit Assouline · McGill University - Dept. Oncology, Jewish General Hospital Site, Montreal QC Canada

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-27
Primary Completion
2018-11-21
Completion
2020-04-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02340780 on ClinicalTrials.gov